novo nordisk semaglutide clinical trials Details of failed studies cast pall on Nordisk's GLP-1 as Alzheimer's treatment Novo Nordisk Sinks on Disappointing

Originally developed for Type 2 diabetes, these medications have gained FDA approval for obesity, reducing risk for heart disease and kidney disease, and treatment of obstructive sleep apnea within the last three years

Its primary function is to stimulate the pituitary gland, a small gland at the base of your brain, to naturally produce and release more of your bodys own human growth hormone (HGH)

Inspect the medicine

The albuminuria-lowering effects of semaglutide are more pronounced in patients with micro- or macroalbuminuria at higher risk, which may translate into larger relative and absolute treatment effects on CV and kidney benefits, but this hypothesis requires confirmation in future studies

This effect persisted even during the post-treatment period